Search results
Showing 121 to 135 of 163 results for fibrosis
Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]
Discontinued Reference number: GID-TA11262
In development Reference number: GID-TA11352 Expected publication date: TBC
from guidance Mannitol dry powder for inhalation for treating cystic fibrosis Number TA266 Date issued November 2012 Other
Faltering growth: recognition and management of faltering growth in children (NG75)
This guideline covers recognition, assessment and monitoring of faltering growth in infants and children. It includes a definition of growth thresholds for concern and identifying the risk factors for, and possible causes of, faltering growth. It also covers interventions, when to refer, service design, and information and support.
Artificial intelligence for analysing chest CT images (MIB243)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated
Urinary tract infection (recurrent): antimicrobial prescribing (NG112)
This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)
Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
Outside interests of the NICE board
NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.